Federico Zappaterra, Domenico Meola, Francesco Presini, Lindomar Alberto Lerin, Pier Paolo Giovannini
{"title":"Do We Still Need Chemistry for Water-Soluble Prodrugs? What Biocatalysis Already Does, and What It Does Not.","authors":"Federico Zappaterra, Domenico Meola, Francesco Presini, Lindomar Alberto Lerin, Pier Paolo Giovannini","doi":"10.3390/pharmaceutics18091166","DOIUrl":null,"url":null,"abstract":"<p><p>Poor aqueous solubility limits roughly 40% of marketed oral drugs and up to ~90% of development candidates. One established remedy is the prodrug strategy: the covalent attachment of a bioreversible promoiety that regenerates the parent drug in vivo. The same conjugation can move a molecule in either direction along the hydrophilic-lipophilic axis: lipophilization raises membrane and oil solubility for permeation-limited or topical uses, whereas hydrophilization raises aqueous solubility. This review addresses hydrophilization and asks whether enzymatic (biocatalytic) synthesis can replace conventional chemistry in building water-soluble prodrugs. We examine, class by class of hydrophilic promoiety (polyol and sugar esters, glycosides, amino acid esters, poly(ethylene glycol), and ionizable phosphates), the biocatalytic toolbox (lipases, acyltransferases, glycosidases, and glycosyltransferases), the molecular determinants of its selectivity, the pharmacokinetic consequences of hydrophilization, and the translation of these reactions to process, benchmarking each against the corresponding chemical route. A three-part test emerges: enzymes suffice, and frequently surpass chemistry, wherever an accessible hydroxyl or carboxyl must be functionalized regioselectively on a promoiety bearing no competing group and a moderate solubility gain is required. This is the regime of polyols, most sugars, and glycosides, with drug-conjugate aqueous-solubility increases of roughly 4-fold to 5500-fold; chemistry remains necessary for ionizable phosphates, amino acid esters, and PEG carriers. Two gaps limit translation: the field's central 'green' claim is asserted far more often than it is measured (E-factor, PMI, life-cycle assessment), and in vivo pharmacokinetic data for enzymatically synthesized hydrophilizing prodrugs remain almost absent. We provide a decision flowchart that assigns each bond of a synthesis to biocatalysis or to chemistry, and reporting guidelines for the seven quantities that make a published E-factor recoverable.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"18 9","pages":""},"PeriodicalIF":6.9000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13610416/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics18091166","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Poor aqueous solubility limits roughly 40% of marketed oral drugs and up to ~90% of development candidates. One established remedy is the prodrug strategy: the covalent attachment of a bioreversible promoiety that regenerates the parent drug in vivo. The same conjugation can move a molecule in either direction along the hydrophilic-lipophilic axis: lipophilization raises membrane and oil solubility for permeation-limited or topical uses, whereas hydrophilization raises aqueous solubility. This review addresses hydrophilization and asks whether enzymatic (biocatalytic) synthesis can replace conventional chemistry in building water-soluble prodrugs. We examine, class by class of hydrophilic promoiety (polyol and sugar esters, glycosides, amino acid esters, poly(ethylene glycol), and ionizable phosphates), the biocatalytic toolbox (lipases, acyltransferases, glycosidases, and glycosyltransferases), the molecular determinants of its selectivity, the pharmacokinetic consequences of hydrophilization, and the translation of these reactions to process, benchmarking each against the corresponding chemical route. A three-part test emerges: enzymes suffice, and frequently surpass chemistry, wherever an accessible hydroxyl or carboxyl must be functionalized regioselectively on a promoiety bearing no competing group and a moderate solubility gain is required. This is the regime of polyols, most sugars, and glycosides, with drug-conjugate aqueous-solubility increases of roughly 4-fold to 5500-fold; chemistry remains necessary for ionizable phosphates, amino acid esters, and PEG carriers. Two gaps limit translation: the field's central 'green' claim is asserted far more often than it is measured (E-factor, PMI, life-cycle assessment), and in vivo pharmacokinetic data for enzymatically synthesized hydrophilizing prodrugs remain almost absent. We provide a decision flowchart that assigns each bond of a synthesis to biocatalysis or to chemistry, and reporting guidelines for the seven quantities that make a published E-factor recoverable.
PharmaceuticsPharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.90
自引率
11.10%
发文量
2379
审稿时长
16.41 days
期刊介绍:
Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.